Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
The Asia Pacific market for aesthetic injectables will show strong growth during the forecast period. This growth will be primarily attributed to the rising adoption of aesthetic procedures in the untapped Chinese and Indian markets. Increasing aesthetic consciousness, growing urban populations with high disposable incomes, and the overall cost effectiveness of these procedures over surgical options are going to be the major drivers in these markets.
This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for aesthetic injectables (including BTX and dermal fillers) in the Asia Pacific region across a 10-year period.
Asia Pacific market will become increasingly competitive over the next ten years.
Which competitors led in the market in 2018?
What strategies have the leading companies been using to maintain market share?
Which domestic companies are performing well in the market, and why?
The Asia Pacific region consists of countries showing diverse aesthetic practices and preferences.
Which countries are close to market saturation, and which still have strong growth potential?
How does product preference differ by country?
How do product ASPs vary across the region?
The dermal filler market will show faster growth in the BTX segment over the forecast period.
What factors will drive this growth?
How will the device preference affect the product launches and ASPs of these devices?
Already a Client? Log in to access this report.
Raghav Tangri is an analyst within the Endoscopy and Aesthetics Medtech Insights team at Decision Resources Group, specializing in facial injectables, hernia repair, and open surgery device markets; he has been featured in the Aesthetics Journal and has participated in several white papers and medtech blogs, with a specific focus on the Indian medical device industry. Raghav holds a Bachelor's degree in Biotechnology from Delhi Technological University and a Master's degree in Life Sciences from Imperial College London.